Bioventix plc
("Bioventix" or the "Company")

Option Exercise, Director/PDMR Shareholding, and Total Voting Rights

​

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 10 April 2025 that 5,204 options were exercised over its ordinary shares of 5 pence each ("Ordinary Shares") by Peter Harrison, Chief Executive Officer, at a price of 1,350 pence per Ordinary Share.

Following this transaction, Mr Harrison's holding in the Company is as detailed below:

Application will be made for 5,204 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to become effective on 16 April 2025. Following Admission, the Company will have 5,224,860 Ordinary Shares in issue. All Ordinary Shares shall have equal voting rights and none of the Ordinary Shares are held in treasury. The total number of voting rights in the Company immediately following Admission will therefore be 5,224,860.

For further information please contact:

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them: